Financials Results for the quarter ended June 30, 2026
RESULTS
▼ Concern Flagged
MEDIUM RISK
📅 Filed on BSE: 21 Jul 2026, 04:47 PM IST · BSE ID: d88c5259-ffbd-4c9e-96bc-ecc4b52334ee
View Original BSE Filing (PDF)
💡
In Simple Terms
The company announced its latest financial results, showing a profit of Rs. 1,020.09 million for the recent quarter.
🤖 AI Summary
- Anthem Biosciences reported standalone profit of Rs. 1,020.09 Mn for quarter ended June 30, 2026.
- Consolidated profit for the quarter ended June 30, 2026, also stood at Rs. 1,020.09 Mn.
- Revenue from operations was Rs. 3,838.42 Mn for the quarter ending June 30, 2026.
- Board approved allotment of 1,670,909 equity shares under the ESOP Scheme 2024.
- Paid-up equity share capital increased to Rs. 1,126.77 Mn as of June 30, 2026.
🔢 Key Numbers — exact figures from BSE filing, not rounded
Revenue from operations (Q1 FY27)
3,838.42 Mn
Revenue from operations (Q1 FY26)
5,380.11 Mn
-28.65%
Profit for the Period (Q1 FY27)
1,020.09 Mn
Profit for the Period (Q1 FY26)
1,483.40 Mn
-31.23%
Basic EPS (Q1 FY26)
2.65
-31.69%
Paid-up equity share capital (June 30, 2026)
1,126.77 Mn
🏢 How This Affects the Company
Revenue from operations for the quarter ended June 30, 2026, was Rs. 3,838.42 Mn, indicating the company's sales performance during this period. The company also noted its wholly owned subsidiary contributed Rs. 358.05 million to total revenue (before consolidation adjustments).
Standalone profit for the period was Rs. 1,020.09 Mn, with total expenses recorded at Rs. 2,760.82 Mn. The paid-up equity share capital increased to Rs. 1,126.77 Mn due to ESOP allotments.
The allotment of 1,670,909 equity shares under the ESOP Scheme 2024 indicates activity in employee remuneration and retention programs.
👥 What This Means For Shareholders
✅
Action Required
No immediate action is required by shareholders based on this financial results filing.
👤
Who Is Affected
Shareholders' equity was affected by the increase in paid-up equity share capital to Rs. 1,126.77 Mn due to the allotment of 1,670,909 ESOP equity shares.
🔍
Management Signal
The management approved unaudited financial results and issued equity shares under an ESOP scheme, indicating continued focus on financial reporting and employee incentives.
For information only. Not investment advice. ForgeUp is not SEBI-registered.
👁 Watch List — track these upcoming events
Q2 FY27 results — monitor revenue and profit trends.
Details on new product launches or business initiatives.
Future updates on ESOP schemes and equity dilution impact.
MEDIUM RISK
The company showed a decline in both revenue and profit for the quarter compared to the previous year.
💡 Investor Takeaway
Anthem Biosciences reported standalone profit of Rs. 1,020.09 Mn for the quarter ended June 30, 2026, a decrease from Rs. 1,483.40 Mn in the prior year's corresponding quarter. Revenue from operations also declined to Rs. 3,838.42 Mn from Rs. 5,380.11 Mn.
⚖️ Strengths & Concerns
✅ Positives
- Profit for the period was Rs. 1,020.09 Mn for the quarter ended June 30, 2026, contributing to overall financial performance.
- Other income of Rs. 286.00 Mn contributed to total income, reflecting diversified revenue streams for the quarter.
⚠️ Concerns
- Revenue from operations decreased to Rs. 3,838.42 Mn for Q1 FY27 from Rs. 5,380.11 Mn in Q1 FY26.
- Profit for the period decreased to Rs. 1,020.09 Mn for Q1 FY27 from Rs. 1,483.40 Mn in Q1 FY26.
❓ Frequently Asked Questions
What was Anthem Biosciences' standalone profit for the quarter ended June 30, 2026?
Anthem Biosciences reported a standalone profit of Rs. 1,020.09 Mn for the quarter ended June 30, 2026.
What was Anthem Biosciences' revenue from operations for Q1 FY27?
Revenue from operations for Anthem Biosciences was Rs. 3,838.42 Mn for the quarter ended June 30, 2026.
How many equity shares did Anthem Biosciences allot under the ESOP Scheme 2024?
Anthem Biosciences allotted 1,670,909 fully paid-up equity shares under the ESOP Scheme 2024 during the quarter.
What was the Basic Earnings Per Share (EPS) for Anthem Biosciences in Q1 FY27?
The Basic Earnings Per Share for Anthem Biosciences was 1.81 for the quarter ended June 30, 2026.
What was Anthem Biosciences' total income for the quarter ended June 30, 2026?
Anthem Biosciences reported a total income of Rs. 4,124.42 Mn for the quarter ended June 30, 2026.
Questions based on this BSE filing only. For information purposes.